Ocata Therapeutics, Inc.: 10-K/A filed 2012-10-26
What Ocata Therapeutics, Inc. reported in its annual report amendment filed 2012-10-26 (fiscal FY 2011): 27 published measures, 71 facts as tagged in accession 0001019687-12-003798.
This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.
This filing
- Form
- 10-K/A (annual report amendment)
- Filed
- 2012-10-26
- Fiscal period
- fiscal FY 2011
- Accession
- 0001019687-12-003798 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Ocata Therapeutics, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 15,185,326 | USD | |
| At 2010-12-31 | 19,054,152 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 59,880,044 | USD | |
| At 2010-12-31 | 41,434,801 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | -46,123,844 | USD | |
| At 2010-12-31 | -23,653,090 | USD | |
| At 2009-12-31 | -46,083,083 | USD | |
| At 2008-12-31 | -35,928,984 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 13,103,007 | USD | |
| At 2010-12-31 | 15,889,409 | USD | |
| At 2009-12-31 | 2,538,838 | USD | |
| At 2008-12-31 | 816,904 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -72,795,119 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -54,373,332 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -36,758,208 | USD | 365 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -13,627,287 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -8,782,932 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -5,142,778 | USD | 365 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 36,830 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 207,402 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 5,368 | USD | 365 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 506,419 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 725,044 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 1,415,979 | USD | 365 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 10,877,715 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 22,353,501 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 6,872,250 | USD | 365 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -36,830 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -219,998 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -7,538 | USD | 365 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | -253,805,438 | USD | |
| At 2010-12-31 | -180,949,523 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 154,771 | USD | |
| At 2010-12-31 | 185,102 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 3,856,501 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 967,721 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 817,444 | USD | 365 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -21,110,358 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -32,328,631 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -10,822,654 | USD | 365 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 13,406,690 | USD | |
| At 2010-12-31 | 15,981,007 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 55,749,567 | USD | |
| At 2010-12-31 | 11,343,120 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 2,128,562 | USD | |
| At 2010-12-31 | 1,982,743 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 21,272,827 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 32,837,075 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 11,737,734 | USD | 365 |
Gross profit
Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 162,469 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 508,444 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 915,080 | USD | 365 |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 343,950 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 216,600 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 500,899 | USD | 365 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 10,021,863 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 8,439,343 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 3,531,540 | USD | 365 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 1,743,569,255 | shares | |
| At 2010-12-31 | 1,439,826,362 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 229,319,208 | USD | |
| At 2010-12-31 | 166,033,976 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2011-12-31 | 2,538,545 | USD | |
| At 2010-12-31 | 4,971,304 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | 11,025,459 | USD | 365 |
| 2010-01-01 to 2010-12-31 | 15,506,191 | USD | 365 |
| 2009-01-01 to 2009-12-31 | 3,439,085 | USD | 365 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-12-31 | -51,684,761 | USD | 365 |
| 2010-01-01 to 2010-12-31 | -22,044,701 | USD | 365 |
| 2009-01-01 to 2009-12-31 | -25,935,554 | USD | 365 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2009-01-01 to 2009-12-31 | -261,504 | USD | 365 |
Inspect the source
- Entity
- Ocata Therapeutics, Inc. / CIK 0001140098
- Captured
- SEC response SHA-256
35ed5f9b7b65d6962e417af6d880d4a32b17c4db50d76618066bbdf10dcb4c40
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001140098.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))